TLDR BOT+BAL delivers 21.2-month median survival in refractory MSS colorectal cancer. Three-year overall survival reaches 33% in Agenus’ fully enrolled Phase 1b cohort. Confirmed response rate hits 21%, including three complete and 23 partial responses. BOT+BAL responses appear e...